Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.
about
Validation of a 4-item score predicting hip fracture and mortality risk among elderly women.Undertreatment of osteoporosis in the oldest old? A nationwide study of over 700,000 older people.Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.Osteosynthetic improvement of osteoporotic bone: prevention surgery.Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer PerspectiveCost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.Treating osteoporosis: economic aspects of bisphosphonate therapy.Non-pharmaceutical prevention of hip fractures - a cost-effectiveness analysis of a community-based elderly safety promotion program in Sweden.National healthcare budget impact analysis of the treatment for osteoporosis and fractures in Korea.Cost-effectiveness of quantitative ultrasound as a technique for screening of osteoporotic fracture risk: report on a health technology assessment conducted in 2001.Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.Estimating the cost effectiveness of alternative drug treatments for postmenopausal osteoporosis.A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures.A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions.Hospitalisations for fracture and associated costs between 2000 and 2009 in Ireland: a trend analysis.Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture.Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway.Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.Evaluation of a program of integrated care to reduce recurrent osteoporotic fractures.Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
P2860
Q33270814-38A59130-446F-4362-A4EC-16F4F27E6712Q33720181-D87715BF-ECEC-4712-9BBD-C80EF6920228Q33841955-5978703A-C812-4A4B-B0D5-D3624AFDBB85Q34497449-B1C16E48-43A1-404A-BFA9-183A24837A7BQ35593305-EE291D27-6E70-4A4C-AA46-F92B7F57E3BBQ36400967-0F8D5B34-0940-4723-9171-16B38FCE9589Q36416737-A1C072F0-A689-467B-AEF7-8F9E4A63D6F9Q36543142-7CDA09C7-731F-4973-A6F3-08E8EEE806DBQ36737876-F811F845-2CF1-48CC-B41D-138C5FC528A0Q37191767-716D46D8-A6E1-4C0F-8436-161428F317B9Q37244022-B780EDD5-EFC9-4ADE-B52F-6F818362FD2FQ37274269-BFDFC384-0131-4BEB-8928-EF95F3909899Q37609360-DD4BA932-82BE-41D4-8806-FE057745AF6DQ38155095-F6FCB034-0C02-49DE-9A8D-7DB2606F0943Q38190449-43C5A859-6421-4B20-B565-6295B4D0EDFDQ39612556-EE844A39-6014-48ED-A18E-154579085223Q43471587-2F3C3D03-7914-428C-933D-4711FEEFE53DQ44669281-A80DE589-1842-46B1-A93A-C948DEC19A2CQ45196993-333DCF01-C08F-4748-AB5B-7DEF840BBC52Q46356238-CBAD7C64-1B7A-492B-8DCD-9C39EB75B434Q46795033-3D1EC037-D0AA-408A-8266-1C46D38B5447
P2860
Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Cost effectiveness of alendron ...... s and prevention of fractures.
@en
Cost effectiveness of alendronate
@nl
type
label
Cost effectiveness of alendron ...... s and prevention of fractures.
@en
Cost effectiveness of alendronate
@nl
prefLabel
Cost effectiveness of alendron ...... s and prevention of fractures.
@en
Cost effectiveness of alendronate
@nl
P2093
P1433
P1476
Cost effectiveness of alendron ...... s and prevention of fractures.
@en
P2093
Bengt Jönsson
Dennis Black
Linus Jönsson
Olof Johnell
P304
P356
10.2165/00019053-200321050-00002
P577
2003-01-01T00:00:00Z
P6179
1027404514